Finnish healthcare company Biohit Oyj has signed a distribution agreement with Canadian Xediton Pharmaceuticals Inc. The agreement covers the distribution and marketing of Biohit product Acetium in Canada.
Acetium is unique and patented product to bind carcinogenic acetaldehyde. The agreement gives Xediton exclusive rights to distribute Acetium products in its market area. Acetium is intended e.g. for persons suffering from atrophic gastritis caused by Helicobacter pylori infection or autoimmune disease. An anacidic stomach is the most significant risk factor in stomach and oesophageal cancer. The risk group includes approximately 500 million people globally
